Meta‐analysis: efficacy of bovine lactoferrin in Helicobacter pylori eradication

Summary Background  Several randomized‐controlled trials (RCTs) have sought to determine the efficacy of bovine lactoferrin in Helicobacter pylori eradication with equivocal results. Aim  To evaluate the effect of bovine lactoferrin supplementation in H. pylori eradication. Methods  Electronic datab...

Full description

Saved in:
Bibliographic Details
Published in:Alimentary pharmacology & therapeutics Vol. 29; no. 7; pp. 720 - 730
Main Authors: SACHDEVA, A., NAGPAL, J.
Format: Journal Article
Language:English
Published: Oxford, UK Blackwell Publishing Ltd 01.04.2009
Blackwell
Subjects:
Anti-Bacterial Agents - therapeutic use
Bacterial diseases
Bacterial diseases of the digestive system and abdomen
Biological and medical sciences
Dietary Supplements
Digestive system
Gastroenterology. Liver. Pancreas. Abdomen
Helicobacter Infections - drug therapy
Helicobacter pylori
Helicobacter pylori - drug effects
Human bacterial diseases
Humans
Infectious diseases
Lactoferrin - therapeutic use
Medical sciences
Pharmacology. Drug treatments
Randomized Controlled Trials as Topic
Spirillales
Bovine
Treatment efficiency
Spirillaceae
Ox
Eradication
Metaanalysis
Infection
Vertebrata
Lactoferrin
Mammalia
Helicobacter pylori
Animal
Bacteriosis
Bacteria
Artiodactyla
Ungulata
ISSN:0269-2813, 1365-2036, 1365-2036
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background  Several randomized‐controlled trials (RCTs) have sought to determine the efficacy of bovine lactoferrin in Helicobacter pylori eradication with equivocal results. Aim  To evaluate the effect of bovine lactoferrin supplementation in H. pylori eradication. Methods  Electronic databases, reviews, bibliographies, s and conference proceedings were searched. Included trials had to be randomized or quasi‐randomized and controlled, using bovine lactoferrin in the intervention group, treating Helicobacter‐infected subjects and evaluating eradication of H. pylori as an outcome. Results  The search identified five eligible RCTs (of 169). Data were available for 682 subjects (bovine lactoferrin group‐n = 316; control group‐n = 366). The pooled odds ratio (five studies) for eradication by intention‐to‐treat analysis was 2.22 (95% CI 1.44–3.44; P = 0.0003) using the fixed effects model (FEM) and 2.24 (95% CI 1.15–4.35; P = 0.0003) using the random effects model (REM) (Cochran’s Q = 6.83; P = 0.145). The pooled risk difference was 0.11 (95% CI 0.05–0.16; P = 0.0001) by FEM (Cochran’s Q = 6.67; P = 0.154) and 0.10 (95% CI 0.04–0.17; P = 0.0023) by REM. There was no significant difference in incidence of adverse effects. Conclusion  Bovine lactoferrin potentially improves H. pylori eradication rates without any impact on adverse effects, but available evidence is limited and further research is necessary to confirm the findings.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0269-2813
1365-2036
1365-2036
DOI:10.1111/j.1365-2036.2009.03934.x